Cyclacel pharmaceuticals reviews 2020 achievements and announces key business objectives for 2021

– anticancer activity of fadraciclib monotherapy in patients with mcl1 amplified solid tumors – – appointment of mark kirschbaum, m.d. as chief medical officer – – $7 million strategic investment by fundamental investor acorn bioventures –

CYCC Ratings Summary

CYCC Quant Ranking